erus BioSciences(CHRS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarterover-quarter– – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – –Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripali ...